GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). GT103 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. GT103 targets the tumor cell-protein complement factor H found on some cancer cells and may provide specific anti-tumor activity that may help block the formation of growths that may become cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving GT103 in combination with pembrolizumab may kill more cancer cells and improve outcomes in patients with advanced or metastatic STK11 mutant non-small cell lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej.
- •Ogólny stan zdrowia pozwalający na aktywność (status ECOG 0-1) przed rozpoczęciem badania.
- •Potwierdzone badaniami laboratoryjnymi obecność mutacji STK11 w raku płuca.
- •Rak płuca, który postępował pomimo leczenia pembrolizumabem lub innym podobnym lekiem (inhibitor PD-1/PD-L1).
- •Dobre wyniki badań krwi wskazujące na prawidłową pracę szpiku kostnego i narządów.
- •Prawidłowa praca nerek (GFR powyżej 45 ml/min).
- •Prawidłowe wyniki badań wątroby (ALT i AST do 3 razy powyżej normy, lub do 5 razy w przypadku przerzutów do wątroby).
- •Prawidłowe wyniki badań serca (troponina I i BNP, frakcja wyrzutowa lewej komory serca).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Roswell Park Cancer Institute
Buffalo, United States
Trial contact
Edwin H. Yau
Edwin H. Yau
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.